Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin

Cardiotoxicity represents the major side-effect limiting the clinical use of anthracyclines, especially doxorubicin, in cancer chemotherapy. The use of non-toxic prodrugs, or of liposome-encapsulated drugs, allows a better targeting of the tumours and may, therefore, improve the tolerance to the tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Platel, D, Bonoron-Adèle, S, Dix, R K, Robert, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374342/
https://www.ncbi.nlm.nih.gov/pubmed/10487608
http://dx.doi.org/10.1038/sj.bjc.6690646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374342/
https://www.ncbi.nlm.nih.gov/pubmed/10487608
http://dx.doi.org/10.1038/sj.bjc.6690646

Ejemplares similares